[1] LASALA GP, MINGUELL JJ. Bone marrow-derived stem/progenitor cells: their use in clinical studies for the treatment of myocardial infarction. Heart Lung Circ. 2009;18(3):171-180.
[2] 林谦,农一兵,万洁,等.慢性心力衰竭中西医结合生存质量量表的临床研究[J].中国中西医结合急救杂志,2008,15(3):131-134.
[3] JADCZYK T, FAULKNER A, MADEDDU P. Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology. Br J Pharmacol. 2013;169(2):247-268.
[4] LI X, HE XT, YIN Y, et al. Administration of signalling molecules dictates stem cell homing for in situ regeneration. J Cell Mol Med. 2017;21(12): 3162-3177.
[5] ULLAH M, LIU DD, THAKOR AS. Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. iScience. 2019;15: 421-438.
[6] 葛均波.我国干细胞治疗心脏病临床研究现状与展望[J].中华心血管病杂志,2006,34(2):97-98.
[7] 吕卓人.从ACC 2005 会议看心力衰竭研究动向[J].中华心血管病杂志,2005,33(12):1150-1153.
[8] CHULLIKANA A, MAJUMDAR AS, GOTTIPAMULA S, et al. Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy. 2015;17(3): 250-261.
[9] LEISTNER DM, FISCHER-RASOKAT U, HONOLD J, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol. 2011;100(10):925-934.
[10] LALU MM, MAZZARELLO S, ZLEPNIG J, et al. Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. Stem Cells Transl Med. 2018;7(12):857-866.
[11] PICINICH SC, MISHRA PJ, MISHRA PJ, et al. The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy. Expert Opin Biol Ther. 2007;7(7):965-973.
[12] BEOHAR N, RAPP J, PANDYA S, et al. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll Cardiol. 2010;56(16):1287-1297.
[13] SANTOS NASCIMENTO D, MOSQUEIRA D, SOUSA LM, et al. Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms. Stem Cell Res Ther. 2014; 5(1):5.
[14] LIU CB, HUANG H, SUN P, et al. Human Umbilical Cord-Derived Mesenchymal Stromal Cells Improve Left Ventricular Function, Perfusion, and Remodeling in a Porcine Model of Chronic Myocardial Ischemia. Stem Cells Transl Med. 2016;5(8):1004-1013.
[15] MICHALICKA M, BOISJOLI G, JAHAN S, et al. Human Bone Marrow Mesenchymal Stromal Cell-Derived Osteoblasts Promote the Expansion of Hematopoietic Progenitors Through Beta-Catenin and Notch Signaling Pathways. Stem Cells Dev. 2017;26(24):1735-1748.
[16] ZHANG W, LIU XC, YANG L, et al. Wharton’s jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction. Coron Artery Dis. 2013; 24(7):549-558.
[17] VIZOSO FJ, EIRO N, CID S, et al. Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. Int J Mol Sci. 2017;18(9). pii: E1852.
[18] FERNÁNDEZ-AVILÉS F, SANZ-RUIZ R, BOGAERT J, et al. Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With ST-Segment Elevation Myocardial Infarction and Left Ventricular Dysfunction. Circ Res. 2018;123(5):579-589. |